Menopause
Menopause is the permanent cessation of menstrual periods, defined as 12 consecutive months without a period in the absence of other causes. It marks the end of a woman's reproductive years and is a natural biological transition, not a disease — but the hormonal changes it brings have far-reaching effects on nearly every organ system, and the years surrounding it are associated with significant health risks that deserve proactive attention.
Menopause occurs because the ovaries exhaust their supply of follicles — the structures that produce eggs and hormones. As follicle reserves deplete, estradiol production falls and follicle-stimulating hormone (FSH) rises. The average age of natural menopause in Western populations is 51, with most women transitioning between ages 45 and 55. Menopause occurring before age 40 is classified as premature ovarian insufficiency (POI) and carries specific clinical implications.
The transition into menopause — called perimenopause — typically begins several years before the final period and is characterized by irregular cycles, fluctuating hormone levels, and the onset of symptoms. It is during perimenopause that many women first notice hormonal changes, even while periods continue.
Stages of the Menopause Transition
Understanding which stage of the transition a woman is in is clinically important and changes how lab results are interpreted.
Perimenopause
The transitional phase preceding menopause. Characterized by menstrual irregularity, fluctuating estradiol levels (which can be highly variable — sometimes elevated, sometimes low), and rising FSH. Symptoms often begin here. Duration is typically 4–8 years.
Menopause
Defined retrospectively after 12 consecutive months without menstruation. Ovarian estradiol production has largely ceased. FSH is persistently elevated. Estradiol is low — typically below 20 pg/mL (73 pmol/L).
Postmenopause
All years following the final menstrual period. Estradiol remains low unless hormone replacement therapy (HRT) is initiated. Long-term health risks — particularly bone loss, cardiovascular changes, and genitourinary symptoms — are most prominent in this phase.
Hormonal Changes at Menopause
The hormonal shifts of menopause are broad and affect multiple axes of the endocrine system.
- Estradiol (E2) — Falls dramatically. The primary ovarian estrogen drops from premenopausal levels of 50–400 pg/mL (depending on cycle phase) to below 10–20 pg/mL. This decline drives the majority of menopausal symptoms and health risks.
- FSH (Follicle-Stimulating Hormone) — Rises markedly. FSH is elevated as the pituitary attempts to stimulate follicles that are no longer responding. Persistently elevated FSH (typically above 25–40 IU/L) is one of the key lab markers of menopause.
- LH (Luteinizing Hormone) — Also rises, though less dramatically than FSH.
- Progesterone — Falls to very low levels as ovulation ceases.
- Testosterone and DHEA-S — Decline gradually. Testosterone production from the ovaries and adrenal glands decreases with age, contributing to low libido and energy.
- SHBG (Sex Hormone-Binding Globulin) — May increase or decrease depending on body weight and HRT type, affecting free hormone levels.
- AMH (Anti-Müllerian Hormone) — Reflects ovarian reserve; falls to undetectable levels at menopause.
Symptoms of Menopause
Menopausal symptoms result primarily from estrogen withdrawal and vary widely in type, severity, and duration between individuals. Some women experience minimal disruption; others are severely affected for a decade or more.
Vasomotor symptoms
- Hot flashes — sudden episodes of intense heat, sweating, and flushing, typically lasting 1–5 minutes
- Night sweats — hot flashes occurring during sleep, frequently disrupting rest
- Cold chills following hot flash episodes
Vasomotor symptoms are the most common and often most disruptive menopausal complaint, affecting up to 75% of women. They can persist for 7–10 years or more in some women.
Genitourinary symptoms (GSM — Genitourinary Syndrome of Menopause)
- Vaginal dryness, thinning, and discomfort
- Pain during intercourse (dyspareunia)
- Urinary urgency, frequency, and increased susceptibility to urinary tract infections
Unlike vasomotor symptoms, GSM tends to worsen over time without treatment rather than improving.
Psychological and cognitive symptoms
- Mood changes, irritability, and anxiety
- Low mood or depression — particularly during perimenopause
- Brain fog, reduced concentration, and memory difficulties
- Sleep disturbances (both from night sweats and from estrogen's direct effect on sleep architecture)
Physical symptoms
- Joint pain and muscle aches
- Skin thinning and dryness
- Hair thinning
- Weight redistribution — particularly increased central (abdominal) adiposity
- Low libido
Long-Term Health Consequences of Menopause
Beyond symptoms, the estrogen deficiency of menopause increases the long-term risk of several serious conditions.
Bone loss and osteoporosis
Estrogen actively suppresses osteoclast activity — the bone-resorbing cells. When estrogen falls at menopause, bone resorption accelerates sharply. Women can lose 1–3% of bone mass per year in the early postmenopausal years. Osteoporosis and fragility fractures are among the most significant long-term health consequences of menopause.
Cardiovascular risk
Before menopause, estrogen has cardioprotective effects — it promotes favorable lipid profiles, maintains vascular flexibility, and reduces inflammatory markers. After menopause, LDL cholesterol typically rises, HDL may fall, and cardiovascular disease risk increases significantly. Heart disease becomes the leading cause of death in postmenopausal women.
Metabolic changes
The shift in fat distribution toward visceral adiposity increases insulin resistance. The risk of type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease rises after menopause.
Cognitive health
Estrogen has neuroprotective properties. The timing of menopause and HRT initiation may influence long-term cognitive health and dementia risk, though research is ongoing.
How Menopause Is Diagnosed
In a woman over 45 with typical symptoms and irregular or absent periods, menopause is often a clinical diagnosis. Lab testing adds precision, particularly for younger women, women with atypical presentations, or women being considered for HRT.
Key diagnostic lab markers
| Marker | What it shows | Typical postmenopausal pattern |
|---|---|---|
| FSH | Primary pituitary signal; rises as ovarian function declines | Persistently elevated >25–40 IU/L |
| Estradiol (E2) | Ovarian estrogen production | Low, typically <20 pg/mL (<73 pmol/L) |
| LH | Pituitary gonadotropin | Elevated |
| AMH | Ovarian reserve | Undetectable or very low |
| Progesterone | Luteal function / ovulation | Very low (no ovulation) |
| TSH | Rule out thyroid dysfunction mimicking menopause | Normal (if no thyroid disease) |
A single FSH measurement can be misleading during perimenopause, when levels fluctuate. Two elevated FSH results at least 4–6 weeks apart, in the context of symptoms and amenorrhea, provide more reliable confirmation.
TSH is worth checking in any woman with significant fatigue, mood changes, or irregular periods, as hypothyroidism can closely mimic perimenopausal symptoms and is common in the same age group.
Perimenopause vs. Menopause — Understanding the Difference
Perimenopause is frequently confused with menopause, and the distinction matters for both diagnosis and management.
During perimenopause, estradiol levels are highly erratic — sometimes within the normal premenopausal range, sometimes elevated (due to abnormal follicular activity), and sometimes very low. FSH is usually elevated but may fluctuate. Periods become irregular. Pregnancy is still possible. Most menopausal symptoms begin during this phase.
A woman is in menopause (retrospectively) when she has had no period for 12 consecutive months. A woman is postmenopausal when she is beyond that point.
This means that many women who feel "menopausal" and have significant symptoms are technically still in perimenopause. This distinction affects both the interpretation of lab results and the options and urgency around treatment decisions.
Hormone Replacement Therapy (HRT)
HRT is the most effective treatment for menopausal symptoms and provides significant long-term bone and potentially cardiovascular protection when initiated in the early postmenopausal years.
What HRT involves
HRT replaces the estrogen (and, in women with a uterus, progesterone) that the ovaries no longer produce. It is available in multiple forms — oral tablets, transdermal patches, gels, sprays, and implants — and the choice of route and formulation is individualized based on symptoms, health history, and preference.
Benefits
- Highly effective relief of vasomotor symptoms and night sweats
- Relief of genitourinary symptoms (topical estrogen)
- Bone protection — reduces fracture risk significantly
- Cardiovascular benefit when started within 10 years of menopause or before age 60 (the "timing hypothesis")
- Improvement in mood, sleep, and cognitive symptoms
Risks and considerations
- Combined estrogen-progestogen HRT is associated with a small increased risk of breast cancer — similar in magnitude to the risk associated with drinking one glass of wine per day
- Estrogen-only HRT (in women without a uterus) has a more favorable safety profile
- Transdermal estrogen avoids first-pass liver metabolism and carries lower VTE (blood clot) risk than oral estrogen
- The benefit-risk balance is generally favorable for healthy women under 60 or within 10 years of menopause onset
Monitoring HRT with labs
Once on HRT, estradiol levels should be measured to confirm adequate absorption and dosing — particularly with transdermal formulations. A therapeutic estradiol target during HRT is generally 50–100 pg/mL (184–367 pmol/L), though this varies by clinical context. FSH may remain elevated even with effective HRT in postmenopausal women and is not a reliable monitoring marker once ovarian function has ceased.
Lab Markers to Track Through the Menopause Transition
The following markers are most useful for diagnosis, monitoring, and long-term health surveillance across the perimenopause and postmenopause:
- Estradiol (E2) — Primary ovarian hormone; confirms menopausal status and monitors HRT adequacy
- FSH — Key marker of menopausal transition; persistently elevated in menopause
- LH — Rises in parallel with FSH
- Progesterone — Confirms absence of ovulation
- AMH — Reflects remaining ovarian reserve; useful in perimenopause
- TSH — Rule out thyroid dysfunction; hypothyroidism is common in this age group and mimics menopausal symptoms
- Lipid panel — Cardiovascular risk rises after menopause; baseline and periodic monitoring warranted
- Fasting glucose and HbA1c — Metabolic risk increases after menopause
- Vitamin D and calcium — Essential for bone health monitoring
- Bone turnover markers (CTX, P1NP) — For women with bone density concerns or on HRT for bone protection
- SHBG — Affects free estradiol and testosterone availability; relevant when assessing HRT adequacy
- Testosterone (total and free) — Declines with age; relevant for women with low libido or fatigue on HRT
Summary
Menopause is a universal biological transition that marks the end of reproductive function, but its hormonal consequences extend far beyond fertility. The estrogen deficiency it brings affects bone density, cardiovascular health, metabolism, cognition, mood, and quality of life — often for decades.
Effective management begins with accurate diagnosis and staging — distinguishing perimenopause from menopause, ruling out conditions that mimic it, and understanding the individual hormone profile. For most symptomatic women, HRT initiated early in the transition offers meaningful symptom relief and long-term health benefits that significantly outweigh the risks.
Regular lab monitoring — particularly of estradiol, FSH, lipids, bone markers, and thyroid function — provides a longitudinal picture of the transition and allows treatment to be individualized and adjusted over time. Tracking these values together, rather than viewing them in isolation, is how informed decisions about menopause management are made.
FAQ: Menopause
What is menopause?
Menopause is defined as 12 consecutive months without a menstrual period, marking the permanent end of ovarian reproductive function. It occurs when the ovaries run out of follicles and stop producing estradiol and progesterone. The average age is 51. Menopause before age 40 is classified as premature ovarian insufficiency and requires separate evaluation.
What is the difference between perimenopause and menopause?
Perimenopause is the transitional phase leading up to menopause — typically lasting 4–8 years — during which periods become irregular, hormone levels fluctuate, and symptoms begin. A woman is in menopause once she has gone 12 months without a period. All years following that point are postmenopause. Many women who feel menopausal are technically still in perimenopause, which affects both lab interpretation and treatment decisions.
What are the symptoms of menopause?
The most common symptoms are hot flashes and night sweats (vasomotor symptoms), vaginal dryness and discomfort, sleep disruption, mood changes, brain fog, low libido, joint pain, and changes in skin and hair. Symptoms vary enormously between individuals — some women have minimal disruption while others experience severe symptoms for a decade or more. Vasomotor symptoms affect up to 75% of women.
What blood tests confirm menopause?
The key markers are FSH and estradiol. In menopause, FSH is persistently elevated (typically above 25–40 IU/L) and estradiol is low (below 20 pg/mL or 73 pmol/L). LH is also elevated. In women over 45 with typical symptoms and absent periods, lab confirmation may not be required. For younger women or atypical presentations, testing is important. TSH should also be checked, as hypothyroidism closely mimics menopausal symptoms.
What is a normal FSH level for menopause?
FSH above 25–40 IU/L on two separate tests taken 4–6 weeks apart, in the context of amenorrhea, is consistent with menopause. FSH levels can fluctuate during perimenopause, so a single elevated result is not definitive. Once fully postmenopausal, FSH typically exceeds 40 IU/L, though lab-specific reference ranges vary.
What is a normal estradiol level after menopause?
In postmenopausal women not taking HRT, estradiol is typically below 10–20 pg/mL (37–73 pmol/L). Women on HRT are generally monitored to a therapeutic target of 50–100 pg/mL (184–367 pmol/L), though optimal targets depend on the formulation used and individual symptoms and response.
What is HRT and who should consider it?
Hormone replacement therapy (HRT) replaces estrogen — and in women with a uterus, progesterone — that the ovaries no longer produce. It is the most effective treatment for vasomotor symptoms, genitourinary symptoms, and bone loss. Current evidence supports HRT for most healthy symptomatic women under 60 or within 10 years of menopause onset, where the benefits generally outweigh the risks. The decision should be individualized based on symptoms, health history, and personal preferences.
Does menopause cause weight gain?
Menopause itself is associated with redistribution of body fat — particularly increased central (abdominal) adiposity — driven by falling estrogen. Total weight gain is also common in midlife, though this is partly attributable to aging, reduced activity, and metabolic changes rather than menopause alone. The central fat redistribution increases cardiovascular and metabolic risk independent of total body weight.
Does menopause cause bone loss?
Yes. Estrogen actively suppresses bone resorption. When estrogen falls at menopause, bone resorption accelerates significantly — women can lose 1–3% of bone mineral density per year in the early postmenopausal period. This accelerated loss is the primary driver of osteoporosis and fragility fractures in women. DEXA scanning and vitamin D and calcium assessment are important for all postmenopausal women, particularly those with additional risk factors.
Can menopause affect the heart?
Yes. Before menopause, estrogen has cardioprotective effects — including favorable effects on cholesterol, vascular function, and inflammation. After menopause, LDL cholesterol typically rises, HDL may fall, and cardiovascular disease risk increases substantially. Heart disease becomes the leading cause of death in postmenopausal women. Lipid monitoring and cardiovascular risk assessment become increasingly important after menopause.
Does menopause affect mood and mental health?
Yes, significantly. Estrogen influences serotonin, norepinephrine, and GABA signaling in the brain. The hormonal fluctuations of perimenopause are associated with increased rates of depression, anxiety, and irritability. Sleep disruption from night sweats compounds mood disturbance. Women with a prior history of depression or PMS are at higher risk. HRT often improves mood symptoms, particularly when they are primarily hormonally driven.
Is it possible to get pregnant during perimenopause?
Yes. Ovulation can still occur during perimenopause, even with irregular periods. Pregnancy is possible until menopause is confirmed (12 months without a period). Contraception should be continued during perimenopause if pregnancy is not desired.
What is the difference between natural menopause and surgical menopause?
Natural menopause occurs gradually as ovarian function declines with age. Surgical menopause occurs when both ovaries are removed (bilateral oophorectomy), causing an immediate and abrupt drop in estrogen rather than a gradual transition. Surgical menopause typically causes more severe symptoms and carries higher long-term risks of bone loss and cardiovascular disease, making HRT especially important for women who undergo it before the natural age of menopause.
What other conditions can mimic menopause?
Several conditions produce symptoms that overlap with menopause: hypothyroidism (fatigue, weight gain, mood changes), hyperthyroidism (hot flashes, palpitations, sweating), hyperprolactinemia (irregular periods, low estrogen), premature ovarian insufficiency (menopause-like symptoms before age 40), and anxiety disorders. This is why TSH and a hormonal panel are valuable parts of the evaluation — particularly in women under 45 or with atypical presentations.
Show more